Results 201 to 210 of about 3,400,908 (256)

Carbon Ion Radiotherapy for Prostate Cancer

Carbon Ion Radiotherapy for Prostate Cancer
NIRS-IMP Joint Symposium on Carbon Ion ...
openaire   +1 more source

Carbon ion radiotherapy for unresectable primary or recurrent soft tissue sarcomas: long-term outcomes based on the local effect model. [PDF]

BMC Cancer
Li P, Li Y, Bao C, Cai X, Wang Z, Zhang Q.   +5 more
europepmc   +1 more source

Carbon Ion Radiotherapy for Retroperitoneal Sarcoma: A Single-Institution Study. [PDF]

Cancers (Basel)
Imai R, Yonemoto T, Araki N, Takiyama H, Ikawa H, Yamada S, Ishikawa H.   +6 more
europepmc   +1 more source

Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer-Achieving higher precision treatment. [PDF]

J Appl Clin Med Phys
Nagata J, Kusano Y, Komori M, Takayama Y, Kurokawa S, Ito A, Kamada T, Yoshida D, Kawashiro S, Katoh H.   +9 more
europepmc   +1 more source

Clinical outcomes of carbon-ion radiotherapy for residual or recurrent hepatocellular carcinoma after transarterial chemoembolization. [PDF]

ESMO Gastrointest Oncol
Sekiguchi Y, Shibuya K, Tomogane S, Miyasaka Y, Kakizaki S, Okamoto M, Araki K, Shirabe K, Ohno T.   +8 more
europepmc   +1 more source

Exploratory case series of conversion to carbon ion radiotherapy after systemic therapy in advanced hepatocellular carcinoma. [PDF]

Int Cancer Conf J
Anzai H, Miwa C, Ogasawara S, Fujiya M, Kurosaki H, Tsuchiya T, Yoshino R, Katayama K, Sawada M, Akatsuka T, Izai R, Yonemoto T, Yumita S, Koroki K, Inoue M, Nakamura M, Kanogawa N, Nakamoto S, Makishima H, Shinoto M, Wakatsuki M, Yamada S, Ishikawa H, Kato J.   +23 more
europepmc   +1 more source

Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab Plus Tremelimumab): A Single-Center Retrospective Study. [PDF]

J Clin Med
Maki K, Haga H, Kaneko T, Hoshikawa K, Katsumi T, Suzuki F, Uchiyama F, Hanatani T, Hagiwara Y, Koto M, Ueno Y.   +10 more
europepmc   +1 more source

MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial. [PDF]

JHEP Rep
Ogasawara S, Koroki K, Makishima H, Wakatsuki M, Takahashi A, Fujiya M, Yumita S, Nakagawa M, Kanzaki H, Kobayashi K, Inoue M, Nakamura M, Kanogawa N, Kondo T, Nakamoto S, Kurokawa T, Ozawa Y, Inaba Y, Paritala S, Chen J, Lee J, Hoshida Y, Hanaoka H, Yamada S, Ishikawa H.   +24 more
europepmc   +1 more source

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol. [PDF]

BMJ Open
Koroki K, Wakatsuki M, Ogasawara S, Makishima H, Watabe T, Anzai H, Fujiya M, Sawada M, Tsuchiya T, Katayama K, Yoshino R, Izai R, Akatsuka T, Miwa C, Yonemoto T, Yumita S, Inoue M, Nakamura M, Kanogawa N, Nakamoto S, Takahashi K, Ozawa Y, Inaba Y, Kurokawa T, Isozaki T, Takahashi A, Kato J, Ohtsuka M, Ohno T, Ueno Y, Furuse J, Kudo M, Hanaoka H, Ishikawa H.   +33 more
europepmc   +1 more source

Development and validation of NTCP models for predicting acute esophagitis in carbon ion radiotherapy for thoracic malignancies. [PDF]

BMC Cancer
Li Y, Zhang L, Liu Y, Ma N, Wu KL, Mao J, Chen J.   +6 more
europepmc   +1 more source